Replimune Exec Sells Shares Under Rule 10b5‑1 Plan Just Weeks Before FDA Review of RP1 Therapy
Insider sale of Replimune shares by CCO Sarchi Christopher hints at cautious confidence amid a looming FDA review of RP1—evaluate the impact on the company’s $694 m market cap.
3 minutes to read